Medac's Rasuvo approved for RA while Antares' injunction is denied

USA-based Medac Pharma, a wholly-owned subsidiary of privately-held German firm medac GmbH, says that the US Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy.

Delivered in an auto-injector, it has been approved for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. Rasuvo will be available in 10 dosage strengths, ranging from 7.5mg to 30mg in 2.5mg increments and will be launched in the USA.

Terri Shoemaker, president and chief executive of Medac Pharma, said: "We're delighted to have secured approval for our lead product, Rasuvo, and look forward to introducing this much-needed therapy to the market. Methotrexate has long been recognized as a mainstay in rheumatoid arthritis therapy. With its virtually painless administration, broad dose range, and significantly enhanced bioavailability, we believe Rasuvo may benefit those patients using methotrexate."